HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MidNite PM “Sleep Fast” And Pain Relief Claims Unsubstantiated – NAD

This article was originally published in The Tan Sheet

Executive Summary

Meda Consumer Healthcare appeals a NAD decision to the National Advertising Review Board. Meda’s evidence failed to show whether its proprietary blend or the individual ingredients provide MidNite PM’s benefits, NAD says, and stating that each ingredient has “calming properties” is “insufficient to support the claim.”

You may also be interested in...



Wink's Ad Claims For Children's Melatonin Fail In Review From J&J Challenge

NAD advises Wink Naturals to discontinue online and social media claims that its melatonin-containing supplements for children are “appropriately dosed for children” and their delivery method is superior to competing products.

In Brief

Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.

US FDA Touts Benefits From Remote Assessments, Manufacturers Feel Burden – Trade Groups

CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel